Can Clovis Oncology (CLVS) reach $32/share?
What’s up with Clovis Oncology?
Clovis Oncology (CLVS) opened at $8.39, which means the stock is up 4.67% from yesterday’s closing price of 7.71. Today, the company has a high of $9.29 and a low of $8.02. The company has a market cap of $593.19 million with a 52-week high of $20.69 and a 52-week low of $2.93.
What about the future for Clovis Oncology?
The high forecast for Clovis Oncology is 32.00 while the low is 3.00. Stock forecasts are based on human experience: Human traders based on their experience in terms of stock price patterns, volume changes, and market news/rumors regarding a particular stock. Clovis Oncology has a strong forecast. A strong forecast is a result of strong earning reports as investors are willing to pay a higher share price today because of growth expectations in the future. Based on this information CLVS seems to be a safe buy.
About Clovis Oncology
Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of cancer treatments. Its marketed product Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is offered for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.